Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2020 2
2021 1
2023 3
2024 3
2025 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

8 results

Results by year

Filters applied: . Clear all
Page 1
Immunogenicity of dupilumab in adult and pediatric patients with atopic dermatitis.
Kamal MA, Kosloski MP, Lai CH, Partridge MA, Rajadhyaksha M, Kanamaluru V, Bansal A, Shabbir A, Shumel B, Ardeleanu M, Richards SM, Yan H, Xu CR, Rodríguez-Marco A, Xiao J, Khokhar FA, Gherardi G, Babilonia E, Maloney J, Mortensen E, Akinlade B, Braunstein N, Stahl N, Torri A, Davis JD, DiCioccio AT. Kamal MA, et al. Front Immunol. 2024 Nov 11;15:1466372. doi: 10.3389/fimmu.2024.1466372. eCollection 2024. Front Immunol. 2024. PMID: 39588375 Free PMC article. Clinical Trial.
METHODS: This analysis included seven phase 3 randomized, placebo-controlled (N=2,992) and two long-term open-label extension (N=2,287) trials of subcutaneous dupilumab in adults and pediatric patients with moderate-to-severe AD. ADA, NAb, and dupilumab concentratio …
METHODS: This analysis included seven phase 3 randomized, placebo-controlled (N=2,992) and two long-term open-label extension (N=2,287) tria …
Immunogenicity of biologics used in the treatment of asthma.
Neunie OAM, Rabbani W, Baker D, Chambers ES, Pfeffer PE, Kang AS. Neunie OAM, et al. Hum Antibodies. 2024;32(3):121-128. doi: 10.3233/HAB-240002. Hum Antibodies. 2024. PMID: 38905039 Review.
SUMMARY: Despite humanization of the antibodies, it is evident that benralizumab; dupilumab; mepolizumab; omalizumab; reslizumab and tezepelumab all induce anti-drug antibodies to some extent. These can contribute to adverse events including infusion reactions, serum …
SUMMARY: Despite humanization of the antibodies, it is evident that benralizumab; dupilumab; mepolizumab; omalizumab; reslizumab and …
Hypersensitivity reactions to biologics used in the treatment of allergic diseases: clinical features, diagnosis and management.
Sitek A, Chiarella SE, Pongdee T. Sitek A, et al. Front Allergy. 2023 Aug 11;4:1219735. doi: 10.3389/falgy.2023.1219735. eCollection 2023. Front Allergy. 2023. PMID: 37637139 Free PMC article. Review.
Several monoclonal antibodies have been approved by the Food and Drug Administration (FDA) to treat allergic disorders, including omalizumab, dupilumab, mepolizumab, reslizumab, benralizumab, tralokinumab and tezepelumab, and their indications continue to expand. ...
Several monoclonal antibodies have been approved by the Food and Drug Administration (FDA) to treat allergic disorders, including omalizumab …
Hypersensitivity and adverse reactions to biologics for asthma and allergic diseases.
Jackson K, Bahna SL. Jackson K, et al. Expert Rev Clin Immunol. 2020 Mar;16(3):311-319. doi: 10.1080/1744666X.2020.1724089. Epub 2020 Feb 8. Expert Rev Clin Immunol. 2020. PMID: 31994421 Review.
Introduction: The development of new biologic agents has provided definite therapeutic advances but, like with any new medications, safety remains a concern.Areas covered: Using PubMed, we reviewed the literature on the adverse effects (AE) to five biologics approved for asthma a …
Introduction: The development of new biologic agents has provided definite therapeutic advances but, like with any new medications, safety r …
Managing a Patient Presenting With Chest Pain and Gastrointestinal Complaints Using Dupilumab.
Alaimo KL, Ramcharan DN, Shaw OG. Alaimo KL, et al. Cureus. 2023 Oct 4;15(10):e46478. doi: 10.7759/cureus.46478. eCollection 2023 Oct. Cureus. 2023. PMID: 37927655 Free PMC article.
We present the case of an 18-year-old male who visited the emergency department on two separate occasions after receiving dupilumab injections for his atopic dermatitis. Ten days prior to his presentation, he was evaluated in the emergency room for the onset of chest pain, …
We present the case of an 18-year-old male who visited the emergency department on two separate occasions after receiving dupilumab i …